Skip to main content
Top
Published in: Infection 1/2020

Open Access 01-02-2020 | Amphotericin B | Original Paper

Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood

Authors: Zoe Oesterreicher, Sabine Eberl, Markus Zeitlinger

Published in: Infection | Issue 1/2020

Login to get access

Abstract

Background

Although fungal infections play a central role in severely ill and immunosuppressed patients, in contrast to antibiotics immunomodulatory effects of antifungals have not been sufficiently investigated. The present study sets out to compare the effect of different antimycotics on immunologic reaction towards mold in vitro.

Materials/methods

Aspergillus fumigatus ATCC204305 was used to develop a model of invasive aspergillosis in vitro in whole blood. Since autoclaved hyphal suspension demonstrated the most potent cytokine release, they were used for the further study including blood of 20 male volunteers. Impact on IL-6, IL-8 and TNF-α time concentration profiles by 5 mg/mL conventional and liposomal amphotericin B, 20 mg/mL fluconazole, 5 mg/mL voriconazole, 2 mg/mL posaconazole or saline solution was investigated over 4 h of incubation at 37 °C.

Results

Compared to baseline, cytokine levels increased by addition of hyphal suspension over 4 h approximately: 54-fold for IL-6, 1000-fold for IL-8 and 270-fold for TNF-α. While conventional amphotericin B further increased IL-6 and to a smaller extent IL-8 levels, this was not the case for its liposomal formulation. Congruently amphotericin B increased cytokines in blood without fungus substantially. Fluconazole reduced cytokine increase for all three cytokines compared to stimulation with hyphae without antifungal agent.

Conclusions

Our data indicate significant differences in the immunomodulatory potency of different antimycotics. While fluconazole had the highest anti-inflammatory potential, conventional amphotericin even increased cytokine release. This preliminary information might have clinical implication, since cytokine dysregulation plays a major role in the pathogenesis and outcome of fungal infections. Clinical studies are warranted to confirm our findings.
Literature
1.
go back to reference Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227–42.CrossRef Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227–42.CrossRef
2.
go back to reference Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704–10.CrossRef Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704–10.CrossRef
3.
go back to reference Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents. 2008;32:39–43.CrossRef Giamarellos-Bourboulis EJ. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents. 2008;32:39–43.CrossRef
4.
go back to reference Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166:1197–205.CrossRef Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166:1197–205.CrossRef
5.
go back to reference Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombolà L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292:156–63.PubMed Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombolà L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292:156–63.PubMed
6.
go back to reference Lotter K, Hocherl K, Bucher M, Kees F. In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice. J Antimicrob Chemother. 2006;58:615–21.CrossRef Lotter K, Hocherl K, Bucher M, Kees F. In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice. J Antimicrob Chemother. 2006;58:615–21.CrossRef
7.
go back to reference Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol. 2008;1:68–79.CrossRef Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol. 2008;1:68–79.CrossRef
8.
go back to reference Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol. 2005;78:135–43.CrossRef Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol. 2005;78:135–43.CrossRef
9.
go back to reference Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005;33:55–70.CrossRef Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005;33:55–70.CrossRef
10.
go back to reference Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359–71.CrossRef Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359–71.CrossRef
11.
go back to reference Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36:612–20.CrossRef Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010;36:612–20.CrossRef
12.
go back to reference Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33:153–9.CrossRef Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J. 2009;33:153–9.CrossRef
13.
go back to reference Cornely OA, Aversa F, Cook P, Jones B, Michallet M, Shea T, et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol. 2011;87:289–301.CrossRef Cornely OA, Aversa F, Cook P, Jones B, Michallet M, Shea T, et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol. 2011;87:289–301.CrossRef
14.
go back to reference Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52:197–205.CrossRef Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52:197–205.CrossRef
15.
go back to reference Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–66.CrossRef Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–66.CrossRef
16.
go back to reference Warris A, Netea MG, Wang JE, Gaustad P, Kullberg BJ, Verweij PE, et al. Cytokine release in healthy donors and patients with chronic granulomatous disease upon stimulation with Aspergillus fumigatus. Scand J Infect Dis. 2003;35:482–7.CrossRef Warris A, Netea MG, Wang JE, Gaustad P, Kullberg BJ, Verweij PE, et al. Cytokine release in healthy donors and patients with chronic granulomatous disease upon stimulation with Aspergillus fumigatus. Scand J Infect Dis. 2003;35:482–7.CrossRef
17.
go back to reference Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11:275–88.CrossRef Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11:275–88.CrossRef
18.
go back to reference Moretti S, Bozza S, Massi-Benedetti C, Prezioso L, Rossetti E, Romani L, et al. An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014;69:1065–74.CrossRef Moretti S, Bozza S, Massi-Benedetti C, Prezioso L, Rossetti E, Romani L, et al. An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014;69:1065–74.CrossRef
19.
go back to reference Choi JH, Kwon EY, Park CM, Choi SM, Lee DG, Yoo JH, et al. Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. Med Mycol. 2010;48:704–9.CrossRef Choi JH, Kwon EY, Park CM, Choi SM, Lee DG, Yoo JH, et al. Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. Med Mycol. 2010;48:704–9.CrossRef
20.
go back to reference Zeitlinger M, Marsik C, Steiner I, Sauermann R, Seir K, Jilma B, et al. Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. J Antimicrob Chemother. 2007;59:219–23.CrossRef Zeitlinger M, Marsik C, Steiner I, Sauermann R, Seir K, Jilma B, et al. Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. J Antimicrob Chemother. 2007;59:219–23.CrossRef
24.
go back to reference Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47:2788–95.CrossRef Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47:2788–95.CrossRef
25.
go back to reference Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583–96.CrossRef Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583–96.CrossRef
26.
go back to reference Vonk AG, Earnest A, Kullberg B-J, Schlamm HT, Chai LYA, Netea MG, et al. Early proinflammatory cytokines and C-reactive protein trends as predictors of outcome in invasive Aspergillosis. J Infect Dis. 2010;202:1454–62.CrossRef Vonk AG, Earnest A, Kullberg B-J, Schlamm HT, Chai LYA, Netea MG, et al. Early proinflammatory cytokines and C-reactive protein trends as predictors of outcome in invasive Aspergillosis. J Infect Dis. 2010;202:1454–62.CrossRef
27.
go back to reference Borger P, Koeter GH, Timmerman JA, Vellenga E, Tomee JF, Kauffman HF. Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis. 1999;180:1267–74.CrossRef Borger P, Koeter GH, Timmerman JA, Vellenga E, Tomee JF, Kauffman HF. Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis. 1999;180:1267–74.CrossRef
28.
go back to reference Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis. 1995;172:1554–60.CrossRef Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis. 1995;172:1554–60.CrossRef
29.
go back to reference Balloy V, Sallenave J-M, Wu Y, Touqui L, Latgé J-P, Si-Tahar M, et al. Aspergillus fumigatus-induced interleukin-8 synthesis by respiratory epithelial cells is controlled by the phosphatidylinositol 3-kinase, p38 MAPK, and ERK1/2 pathways and not by the toll-like receptor-MyD88 pathway. J Biol Chem. 2008;283:30513–21.CrossRef Balloy V, Sallenave J-M, Wu Y, Touqui L, Latgé J-P, Si-Tahar M, et al. Aspergillus fumigatus-induced interleukin-8 synthesis by respiratory epithelial cells is controlled by the phosphatidylinositol 3-kinase, p38 MAPK, and ERK1/2 pathways and not by the toll-like receptor-MyD88 pathway. J Biol Chem. 2008;283:30513–21.CrossRef
30.
go back to reference Shen HP, Tang YM, Song H, Xu WQ, Yang SL, Xu XJ. Efficiency of interleukin 6 and interferon gamma in the differentiation of invasive pulmonary aspergillosis and pneumocystis pneumonia in pediatric oncology patients. Int J Infect Dis. 2016;48:73–7.CrossRef Shen HP, Tang YM, Song H, Xu WQ, Yang SL, Xu XJ. Efficiency of interleukin 6 and interferon gamma in the differentiation of invasive pulmonary aspergillosis and pneumocystis pneumonia in pediatric oncology patients. Int J Infect Dis. 2016;48:73–7.CrossRef
31.
go back to reference Heldt S, Prattes J, Eigl S, Spiess B, Flick H, Rabensteiner J, et al. Diagnosis of invasive aspergillosis in hematological malignancy patients: performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect. 2018;77:235–41.CrossRef Heldt S, Prattes J, Eigl S, Spiess B, Flick H, Rabensteiner J, et al. Diagnosis of invasive aspergillosis in hematological malignancy patients: performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect. 2018;77:235–41.CrossRef
32.
go back to reference Gresnigt MS, Rekiki A, Rasid O, Savers A, Jouvion G, Dannaoui E, et al. Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the interleukin-1 receptor. Sci Rep. 2016;6:26490.CrossRef Gresnigt MS, Rekiki A, Rasid O, Savers A, Jouvion G, Dannaoui E, et al. Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the interleukin-1 receptor. Sci Rep. 2016;6:26490.CrossRef
33.
go back to reference Louie A, Baltch AL, Franke MA, Smith RP, Gordon MA. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother. 1994;34:975–87.CrossRef Louie A, Baltch AL, Franke MA, Smith RP, Gordon MA. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother. 1994;34:975–87.CrossRef
34.
go back to reference Simitsopoulou M, Roilides E, Dotis J, Dalakiouridou M, Dudkova F, Andreadou E, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother. 2005;49:1397–403.CrossRef Simitsopoulou M, Roilides E, Dotis J, Dalakiouridou M, Dudkova F, Andreadou E, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother. 2005;49:1397–403.CrossRef
35.
go back to reference Simitsopoulou M, Roilides E, Walsh TJ. Immunomodulatory properties of antifungal agents on phagocytic cells. Immunol Invest. 2011;40:809–24.CrossRef Simitsopoulou M, Roilides E, Walsh TJ. Immunomodulatory properties of antifungal agents on phagocytic cells. Immunol Invest. 2011;40:809–24.CrossRef
36.
go back to reference Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 1995;38:459–65.CrossRef Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 1995;38:459–65.CrossRef
37.
go back to reference Pawelec G, Ehninger G, Rehbein A, Schaudt K, Jaschonek K. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. Int J Immunopharmacol. 1991;13:299–304.CrossRef Pawelec G, Ehninger G, Rehbein A, Schaudt K, Jaschonek K. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. Int J Immunopharmacol. 1991;13:299–304.CrossRef
38.
go back to reference Kalkanci A, Kustimur S. The effect of fluconazole treatment on tumor necrosis factor-alpha production in murine candidiasis. Yale J Biol Med. 2002;75:241–5.PubMedPubMedCentral Kalkanci A, Kustimur S. The effect of fluconazole treatment on tumor necrosis factor-alpha production in murine candidiasis. Yale J Biol Med. 2002;75:241–5.PubMedPubMedCentral
39.
go back to reference Filler SG, Sheppard DC. Fungal invasion of normally non-phagocytic host cells. PLoS Pathog. 2006;2:e129.CrossRef Filler SG, Sheppard DC. Fungal invasion of normally non-phagocytic host cells. PLoS Pathog. 2006;2:e129.CrossRef
40.
go back to reference Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol. 2010;150:406–17.PubMed Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol. 2010;150:406–17.PubMed
41.
go back to reference Chotirmall SH, Al-Alawi M, Mirkovic B, Lavelle G, Logan PM, Greene CM, et al. Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int. 2013;2013:723129.CrossRef Chotirmall SH, Al-Alawi M, Mirkovic B, Lavelle G, Logan PM, Greene CM, et al. Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int. 2013;2013:723129.CrossRef
Metadata
Title
Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood
Authors
Zoe Oesterreicher
Sabine Eberl
Markus Zeitlinger
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2020
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01346-x

Other articles of this Issue 1/2020

Infection 1/2020 Go to the issue